Antiphospholipid Antibodies (aPL) Increase The Potential Monocyte Procoagulant Activity in Patients with Systemic Lupus Erythematosus  

Oleh:

Martini, F ; Farsi, A ; Gori, AM ; Boddi, M ; Fedi, S ; Domeneghetti, MP ; Passaleva, A ; Prisco, D ; Abbate, Rosanna

Jenis: Article from Journal
Dalam koleksi: Lupus vol. 5 no. 3 (1996), page 206-211.
Topik: Procoagulant Activity; Monocyte; Antiphospholipid Antibodies; SLE
Fulltext: 206.full.pdf (549.66KB)

Isi artikel

Lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) are frequently detected in sera from patients affected by systemic lupus erythematosus (SLE). However, the role of antiphospholipid antibodies (aPL) in thrombus formation has not been defined as yet. Twenty-two patients affected by SLE, all fulfilling the 1982 ARA revised criteria, and twenty healthy subjects were investigated for the presence of LA, aCL and other aPLs. Monocyte procoagulant activity-PCA (Tissue Factor production) was evaluated by one stage plasma recalcification time. In all patients the plasma levels of F1 + 2 and of plasminogen activator inhibitor (PAI) were also determined. Monocyte PCA was significantly higher in SLE patients with LA and/or aCL in comparison to SLE patients without LA and/or aCL (p < 0.01) and to controls (p < 0.05). However, no connection was observed between PCA expression by mononuclear cells and LA or aCL levels. No differences in F1 + 2 and PAI plasma levels were found between SLE patients with or without aPL and controls. In our SLE patients LA and/or aCL positivity appears strictly related to an increased monocyte activation that could play an important role in the occurrence of thrombotic events.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali